- A study shows that upon treating cells with Growth Factor Z, the cellular concentration of Molecule A increases, and simultaneously, the activity of Enzyme B increases. The researchers conclude that Molecule A is an activator of Enzyme B. Why is this conclusion only correlational and not definitively causal?
Answer: Growth Factor Z might activate Enzyme B through a separate signaling pathway that is independent of the Molecule A concentration increase.
Correlation does not equal causation. The observation that A and B both increase after a single stimulus (Growth Factor Z) does not prove that A causes the increase in B. It is entirely possible that the growth factor initiates two parallel, independent signaling cascades: one that leads to more Molecule A, and another that activates Enzyme B. This is a classic 'third variable' problem where the growth factor is the third variable causing both effects. To establish causality, one would need to manipulate Molecule A directly and observe the effect on Enzyme B. The other options describe issues of technical artifact (B), temporality (C), or statistical significance (D), but (A) addresses the core logical flaw in the causal inference.
- A researcher is investigating the effect of a novel enzyme inhibitor on cellular respiration. They measure oxygen consumption in isolated mitochondria under four conditions: (1) mitochondria alone, (2) mitochondria + ADP + Pi, (3) mitochondria + ADP + Pi + inhibitor, and (4) mitochondria + inhibitor (no ADP/Pi). Which of the following represents the most critical control missing from this experimental design?
Answer: A condition with mitochondria + ADP + Pi + vehicle control (solvent without inhibitor) to account for potential solvent effects on oxygen consumption
The most critical missing control is the vehicle control (A). Since inhibitors are typically dissolved in solvents like DMSO or ethanol, it's essential to test whether the solvent itself affects oxygen consumption. Without this control, any observed inhibition could be due to the solvent rather than the inhibitor compound. Choice B tests inhibitor specificity but is less critical since chemical oxygen consumption would be obvious. Choice C provides a positive control for electron transport function but isn't addressing a potential confound. Choice D shows maximal capacity but doesn't control for confounding variables.
- A biochemistry laboratory is investigating the substrate specificity of a newly discovered protease. They test the enzyme against four different peptide substrates and measure initial reaction rates. However, they notice that one substrate (Substrate C) shows unusually high apparent activity compared to the others. Which of the following represents the most likely confounding factor that could explain this unexpected result?
Answer: Substrate C spontaneously hydrolyzes under the reaction conditions (pH 8.0, 37°C), contributing non-enzymatic cleavage that is incorrectly attributed to enzyme activity
Spontaneous hydrolysis (C) is the most likely confounding factor. Some peptide bonds are inherently unstable under certain pH and temperature conditions, leading to non-enzymatic cleavage that would be detected as apparent enzyme activity. This is a common issue in protease assays and should be controlled for with enzyme-free reactions. Choice A describes interference but fluorescent amino acids typically don't cause overestimation in standard protease assays. Choice B could affect reaction rates but is less likely to cause dramatic differences. Choice D represents an experimental error in preparation rather than a confounding factor inherent to the substrate.
- A researcher hypothesizes that nutrient depletion induces the expression of Gene P. They grow one culture of cells in a rich, complete medium (Fed) and another in a nutrient-deficient medium (Starved) for 48 hours. qPCR analysis shows that the mRNA level of Gene P is five-fold higher in the Starved culture. Besides nutrient levels, what is the most likely confounding variable that could explain this result?
Answer: The two cell cultures have likely reached different stages of the cell growth cycle or density.
When evaluating gene expression experiments, you must consider all variables that could influence your results beyond your intended experimental condition. This question tests your ability to identify the most significant confounding factor in a controlled experiment.
The correct answer is D because cell growth stage and density dramatically affect gene expression patterns. After 48 hours, the Fed culture likely reached stationary phase with high cell density, while the Starved culture remained in an earlier growth phase with lower density. Different growth phases trigger distinct transcriptional programs - many genes are naturally upregulated during slower growth or stress conditions, which could easily account for the five-fold increase in Gene P expression independent of the nutrient depletion hypothesis.
Option A is incorrect because lower total RNA extraction doesn't affect qPCR results when properly normalized. qPCR measures relative gene expression ratios, not absolute RNA amounts. Option B, while pH changes can affect gene expression, is much less likely to cause such a dramatic and specific five-fold increase compared to the profound effects of growth phase differences. Option C is wrong because qPCR primer efficiency would be determined by the target sequence itself, not the sample type - the same Gene P sequence exists in both cultures.
Remember that in gene expression studies, growth phase is one of the most powerful variables affecting transcription. Always consider whether compared samples are at equivalent growth stages and cell densities. This is why proper experimental design includes growth curve analysis and standardized harvest timepoints.
- A research team is investigating whether a specific metabolite regulates enzyme activity in liver cells. They design an experiment using cell-free liver extracts incubated with varying concentrations of the metabolite, then measure target enzyme activity. After 2 hours of incubation, they observe a dose-dependent decrease in enzyme activity. Which control experiment would be most critical for validating their conclusion that the metabolite directly regulates the enzyme?
Answer: Incubate the purified target enzyme (isolated from the cell extract) with the metabolite under identical conditions to verify direct enzyme-metabolite interaction
Testing the purified enzyme (B) is most critical because cell extracts contain numerous proteins that could mediate indirect effects. The metabolite might regulate the target enzyme indirectly through kinases, phosphatases, or other regulatory proteins present in the extract. Only by testing the isolated enzyme can researchers determine if the regulation is direct. Choice A tests specificity but doesn't address direct vs. indirect mechanisms. Choice C considers metabolite stability, which is important but secondary to the direct/indirect question. Choice D addresses kinetics but time-dependent effects don't necessarily indicate indirect regulation.
- In a study of membrane protein function, researchers use patch-clamp electrophysiology to measure ion channel activity in the presence and absence of a potential modulator compound. They observe that the compound appears to increase channel open probability from 0.3 to 0.7. However, three graduate students in the lab consistently obtain different baseline open probabilities (0.2, 0.3, and 0.5) for the same channel under identical conditions. What experimental modification would best address this reproducibility issue?
Answer: Implement a standardized cell preparation protocol including specific culture conditions, passage numbers, and membrane patch selection criteria to reduce biological variability between experiments
Standardized cell preparation protocols (A) address the most likely source of variability in patch-clamp experiments. Factors like cell passage number, culture density, membrane health, and patch selection criteria dramatically affect baseline channel properties. Standardization reduces biological and technical variability between experimenters. Choice B addresses equipment variability but is impractical for routine experiments and doesn't solve the fundamental reproducibility issue. Choice C helps with data normalization but doesn't eliminate the underlying variability. Choice D increases statistical power but doesn't address the root cause of inter-experimenter differences.
- To test if protein X and protein Y interact, a researcher mixes them and applies the sample to a size-exclusion chromatography column. A single peak is observed at an elution volume corresponding to a molecular weight larger than either X or Y alone. The researcher concludes that X and Y have formed a stable complex. Which essential control is missing to properly interpret this result?
Answer: Each protein, X and Y, must be run individually on the same column under identical conditions.
When evaluating protein-protein interactions using size-exclusion chromatography, you're separating molecules based on their size - larger complexes elute earlier than smaller individual proteins. The key principle is that if two proteins interact, their combined molecular weight should produce a peak at a different elution volume than either protein alone.
The researcher observed a single peak at higher molecular weight, suggesting complex formation. However, without running proteins X and Y individually under identical conditions, you cannot definitively conclude they're interacting. The individual runs establish the baseline elution volumes for each protein alone, allowing you to compare these to the mixed sample. Only then can you determine if the observed peak truly represents a complex or if one protein naturally elutes at that position.
Option A is useful but secondary - SDS-PAGE analysis would confirm both proteins are present in the peak, but doesn't address the fundamental control issue. Option B assumes the column isn't already calibrated, which is typically done during setup and isn't the missing experimental control. Option D suggests adding a non-interacting protein, which could provide additional evidence but isn't essential for interpreting the basic result.
The individual protein runs in option C provide the critical reference points that make the data interpretable. Without knowing where X and Y elute separately, you cannot conclude that the observed peak represents an interaction.
Study tip: In protein interaction experiments, always ask "What are the appropriate controls?" Individual component runs are essential baselines for any binding or interaction assay.
- A researcher observes that treating cultured muscle cells with the hormone Adrenaline increases the rate of glycogenolysis. It is known that Adrenaline acts via a cell surface β-adrenergic receptor. To provide the most direct evidence that this specific receptor is required for the observed effect, which experiment should be performed?
Answer: Repeat the experiment using cells pre-treated with a potent, specific antagonist of the β-adrenergic receptor before adding Adrenaline.
When you encounter questions about proving a specific receptor's role in a biological response, you need to think about experimental controls and the most direct way to establish causation.
The correct approach is C because using a specific β-adrenergic receptor antagonist provides the most direct test of whether this particular receptor mediates the effect. If you block the receptor with an antagonist and the adrenaline-induced glycogenolysis is prevented or significantly reduced, you've directly demonstrated that this specific receptor is required for the response. This is a classic pharmacological approach that isolates the variable you're testing.
A is incorrect because a dose-response curve only tells you about the potency and efficacy of adrenaline, not which specific receptor mediates the effect. Adrenaline could theoretically work through other receptors at different concentrations.
B is wrong because measuring cAMP only confirms that the known signaling pathway is active, but doesn't prove that the β-adrenergic receptor specifically is required. Other receptors could also activate adenylyl cyclase and increase cAMP.
D is incorrect because testing insulin merely shows that the glycogen metabolism machinery works bidirectionally (insulin promotes glycogen synthesis), but provides no information about which receptor mediates adrenaline's effects.
Key strategy: In receptor pharmacology questions, look for experiments using specific antagonists or receptor knockouts—these provide the most direct evidence for a receptor's necessity in a particular response. Control experiments should isolate the single variable being tested.
- An investigator tests a potential drug on the glycolytic pathway by measuring lactate production from cultured cells. The drug is supplied as an acidic salt, and its addition to the culture medium lowers the pH from 7.4 to 6.9. An increase in lactate production is observed. The investigator concludes the drug directly stimulates a glycolytic enzyme. Why is this conclusion potentially flawed?
Answer: The activity of key glycolytic enzymes, such as phosphofructokinase-1, is highly sensitive to pH, and the pH drop itself could alter the pathway's flux.
When analyzing experimental results involving metabolic pathways, you must always consider whether observed effects are due to the drug itself or to changes in experimental conditions. This question tests your understanding of how environmental factors can confound biochemical experiments.
The correct answer is D because phosphofructokinase-1 (PFK-1), the rate-limiting enzyme of glycolysis, is exquisitely sensitive to pH changes. PFK-1 activity increases significantly as pH drops from 7.4 to 6.9, which would directly stimulate glycolytic flux and increase lactate production. This pH effect alone could explain the results without any direct drug action on glycolytic enzymes, making the investigator's conclusion premature.
Option A is incorrect because while membrane damage could release intracellular lactate, a pH drop from 7.4 to 6.9 is relatively modest and unlikely to cause significant membrane disruption in cultured cells. Option B reverses cause and effect – the pH drop occurred immediately upon drug addition (before significant lactate could accumulate), so the acidification caused increased lactate production, not vice versa. Option C incorrectly suggests reduced drug uptake at lower pH would be problematic, but this would decrease, not increase, any drug effect on lactate production.
The key lesson: always consider whether changes in experimental conditions (pH, temperature, ionic strength) could independently affect the biological system you're studying. In metabolic experiments, pH effects on enzyme activity are particularly important confounding variables to control for.
- A laboratory is developing a new enzyme assay to measure lipase activity in blood samples. They test their method using known concentrations of purified lipase spiked into pooled serum samples. The assay shows excellent linearity and precision with purified enzyme, but when they test actual patient samples, they observe highly variable results that don't correlate with clinical symptoms. Which factor most likely explains the discrepancy between the purified enzyme validation and patient sample results?
Answer: Patient serum contains endogenous inhibitors or activators of lipase that are absent in the purified enzyme system, leading to variable apparent enzyme activity depending on individual patient biochemistry
When developing enzyme assays, you must consider the difference between controlled laboratory conditions using purified reagents versus the complex biological environment of actual patient samples. This question tests your understanding of how endogenous factors can interfere with enzyme activity measurements.
The correct answer is D because patient serum contains a complex mixture of proteins, cofactors, and regulatory molecules that can significantly affect lipase activity. These include natural inhibitors like apolipoprotein C-II deficiency states, bile salt concentrations that affect lipase activation, and varying levels of cofactors like colipase that are essential for optimal lipase function. Unlike purified enzyme systems tested in controlled buffer conditions, patient samples represent the true physiological environment where these regulatory factors create patient-to-patient variability in apparent enzyme activity.
Option A is incorrect because proper validation protocols would include stability testing under various storage conditions, and this wouldn't explain the lack of correlation with clinical symptoms. Option B misses the mark because substrate specificity issues would show up during the purified enzyme validation phase, not just with patient samples. Option C describes a common analytical interference, but hemolysis effects would be easily identified and controlled for in a well-designed assay protocol.
Remember that when enzyme assays work well with purified systems but fail in biological samples, look for endogenous regulatory factors first. The biological context almost always introduces variables absent in simplified laboratory conditions, making this a key consideration in clinical biochemistry assay development.
- A graduate student designs an experiment to test whether a specific amino acid residue is essential for enzyme activity. They create a point mutation (Asp127→Ala) and measure enzyme activity. The wild-type enzyme shows 100% activity, while the mutant shows 15% activity. The student concludes that Asp127 is critical for catalysis. Which experimental approach would provide the strongest evidence to support or refute this conclusion?
Answer: Measure the thermal stability and CD spectrum of both wild-type and mutant proteins to ensure that the mutation does not cause global protein misfolding
The strongest evidence comes from verifying protein folding integrity (B). If the Asp127Ala mutation causes protein misfolding, the reduced activity would be an indirect effect rather than evidence that Asp127 is specifically involved in catalysis. CD spectroscopy and thermal stability measurements can reveal if the protein maintains proper secondary/tertiary structure. Choice A provides useful information about charge requirements but doesn't address the fundamental question of whether the protein is properly folded. Choice C gives mechanistic details but assumes the protein is folded correctly. Choice D addresses protein concentration but not structural integrity.
- A biochemist is testing a newly synthesized compound, 'Inhibitor X', for its effect on the enzyme lactase. An experiment is run containing lactase, its substrate lactose, and Inhibitor X in a buffer. To conclusively determine if Inhibitor X is reducing the enzyme's catalytic rate, which of the following is the most essential control experiment?
Answer: A reaction containing lactase and lactose in the same buffer, but without Inhibitor X.
To claim that a compound inhibits an enzyme, one must first establish the enzyme's baseline activity under the same conditions but in the absence of the inhibitor. This 'no inhibitor' control (A) provides the reference rate to which the inhibited rate is compared. Choice (B) is a control for non-enzymatic substrate breakdown, which is useful but not as critical as the baseline activity. Choice (C) contains no substrate and thus would show no reaction, providing no useful rate information. Choice (D) is a positive control, which demonstrates that inhibition can be detected in the assay, but it doesn't help determine if Inhibitor X itself is effective.
- In a metabolomics study, researchers use LC-MS to compare metabolite levels between control and treated cells. They notice that several metabolites show apparent increases in the treated samples, but the increases are not consistent across different experimental days. The same batch of cells and treatment were used throughout. Which quality control measure would be most effective in identifying whether this day-to-day variation represents real biological differences or analytical artifacts?
Answer: Run a pooled quality control sample (mixture of all samples) at regular intervals throughout each analytical batch to monitor instrument performance and signal drift
When analyzing metabolomics data with day-to-day variation, you need to distinguish between true biological effects and systematic analytical drift that affects all samples similarly over time. This is a classic quality control challenge in analytical chemistry.
Option D is correct because pooled quality control (QC) samples contain the same mixture of metabolites run repeatedly throughout each batch. If the apparent increases in treated samples are due to instrument drift, sensitivity changes, or other analytical artifacts, you'll see the same pattern of increase in the pooled QC samples over time. Since the pooled QC has a constant composition, any changes in signal must be analytical artifacts. If the QC samples remain stable while treated samples show increases, then the treatment effect is likely real.
Option A addresses experimental design for biological variation but won't identify analytical artifacts that affect all samples on a given day equally. Option B focuses on injection precision, which measures short-term reproducibility but won't detect the systematic day-to-day drift described in the question. Option C helps with sample-to-sample normalization and reduces bias from analysis order, but internal standards added to individual samples won't reveal instrument-wide performance changes over days.
For metabolomics troubleshooting, remember that pooled QC samples are your best tool for detecting systematic analytical problems because they provide a constant biological matrix to monitor instrument performance over time. Look for parallel trends between your samples of interest and the QC samples to identify analytical artifacts.
- An enzyme's activity is reduced in the presence of Molecule Z. Kinetic analysis reveals that Molecule Z decreases Vmax but does not change Km. A researcher concludes that Molecule Z must be an allosteric inhibitor. Why is this conclusion not fully supported by the kinetic data alone?
Answer: A non-allosteric, noncompetitive inhibitor that binds equally well to the free enzyme and the enzyme-substrate complex would produce the identical kinetic pattern.
This question highlights the distinction between a kinetic description ('noncompetitive inhibition') and a structural mechanism ('allosteric inhibition'). The kinetic pattern of decreased Vmax with no change in Km defines noncompetitive inhibition. While many allosteric inhibitors exhibit this pattern, it is not proof of an allosteric mechanism. A classical noncompetitive inhibitor could, in theory, bind somewhere in or near the active site (not an allosteric site) in such a way that it prevents catalysis but doesn't affect substrate binding. Thus, kinetics alone cannot distinguish these structural possibilities. Uncompetitive inhibition (B) has a different kinetic signature (decreased Vmax and Km). While (C) and (D) are possible issues, (A) points out the fundamental limitation in equating a kinetic pattern with a specific structural mechanism.
- A study compares fatty acid oxidation in two groups of mice: a wild-type (WT) group and a transgenic (TG) group overexpressing a metabolic enzyme. The TG mice show a higher rate of fatty acid oxidation. However, the researchers also note that the TG mice are significantly more active and aggressive than the WT mice. How does this behavioral difference confound the metabolic conclusion?
Answer: Increased physical activity would independently increase the demand for energy, thereby stimulating fatty acid oxidation, regardless of the transgene's direct effect.
When evaluating experimental results, you must always consider confounding variables—factors that could influence your outcome independently of the variable you're actually testing. In metabolic studies, behavioral differences can be major confounders because behavior directly affects energy demand.
The key insight here is that increased physical activity creates an independent metabolic demand. When the transgenic mice are more active and aggressive, their muscles require more ATP to fuel movement and behavioral responses. This increased energy demand naturally stimulates fatty acid oxidation through normal metabolic pathways, regardless of what the overexpressed enzyme might be doing. You can't determine whether the higher oxidation rate comes from the transgene's direct biochemical effect or simply from the mice needing more energy for their hyperactive behavior. This makes option B correct.
Looking at the distractors: Option A focuses on stress affecting the wild-type mice, but the confounding issue is with interpreting the transgenic mice's results, not problems with the control group. Option C suggests altered food consumption, but this doesn't address the core issue—even with identical food intake, more active mice would still oxidize more fatty acids to meet their energy demands. Option D mentions measurement errors from handling difficulties, but this is about technical issues rather than the biological confounding that makes the results uninterpretable.
Remember: in biochemistry experiments, always ask whether behavioral, environmental, or physiological differences could independently affect the metabolic pathway you're studying. Activity level is one of the strongest confounders in metabolic research.
- A researcher uses an electrophoretic mobility shift assay (EMSA) to test the hypothesis that transcription factor 'TF-A' specifically binds to a DNA sequence 'Seq-X'. They observe that when radiolabeled Seq-X is incubated with purified TF-A, a portion of the radioactivity shifts to a higher molecular weight band. To provide the strongest evidence for binding specificity to Seq-X, what additional experiment is most crucial?
Answer: A competition assay including TF-A, radiolabeled Seq-X, and a large excess of unlabeled Seq-X.
To demonstrate specificity, one must show that the interaction can be specifically competed away. Adding a large excess of unlabeled, 'cold' specific competitor (unlabeled Seq-X) should cause a decrease in the shifted radiolabeled band, as the labeled and unlabeled DNA compete for the same binding site on TF-A. While a non-specific DNA competitor (D) is also a very important control to show the protein doesn't bind just any DNA, the specific competitor (A) is the most direct test of the specific interaction with Seq-X. Higher salt (B) tests interaction strength, not sequence specificity. Using another protein (C) tests the uniqueness of TF-A, not its sequence preference.
- A scientist compares the stability of a wild-type (WT) enzyme and a mutant (MT) version. Both are incubated at 45°C, and samples are taken every 10 minutes to measure remaining activity. The data show that the MT enzyme loses a greater percentage of its initial activity over time. However, a crucial control measurement was omitted. Which missing piece of information represents the most significant potential confound?
Answer: The specific activity of each enzyme (e.g., in U/mg) at time zero under standard assay conditions.
When evaluating enzyme stability experiments, you must distinguish between measuring enzyme degradation versus measuring enzyme activity changes. This question tests whether you understand what controls are necessary to draw valid conclusions about protein stability.
The correct answer is C because specific activity (units of activity per mg of protein) tells you how much active enzyme you're starting with in each sample. Without knowing the initial specific activities, you can't determine whether the mutant's greater activity loss is due to thermal instability or simply because it started with lower activity. For example, if the wild-type has 100 U/mg and the mutant has 20 U/mg at time zero, both at the same protein concentration, then comparing percentage activity loss becomes meaningless—you're comparing apples to oranges.
Option A is incorrect because equal protein concentrations don't ensure equal amounts of active enzyme if the proteins have different specific activities. Option B is wrong because substrate concentration affects the absolute activity readings but wouldn't differentially impact the comparison between wild-type and mutant if both are assayed under identical conditions. Option D, while scientifically valuable, isn't the most significant confound here—you can observe stability differences without knowing melting temperatures, but you cannot interpret activity loss data without knowing baseline specific activities.
Study tip: In enzyme stability experiments, always ensure you're comparing equivalent amounts of active enzyme at the start. Protein concentration alone isn't sufficient—you need activity per unit protein to make valid comparisons.
- A researcher treats cells with a drug and wants to see if it increases the amount of protein P. They perform an SDS-PAGE and Western blot on lysates from untreated (control) and treated cells. The blot, probed with an antibody for protein P, shows a much darker band in the treated lane. To validly conclude that the total amount of protein P per cell has increased, what is the most critical additional step?
Answer: The blot must be stripped and re-probed with an antibody for a loading control protein, like actin or tubulin, to normalize the data.
When analyzing Western blot results, the fundamental principle is that you're comparing relative protein amounts between samples. However, experimental variables like pipetting errors, cell counting mistakes, or differences in cell lysis efficiency can create misleading results that have nothing to do with actual protein expression changes.
Option B is correct because loading control normalization is essential for valid quantitative comparisons. Even if you see a darker band for protein P in the treated lane, this could simply mean you loaded more total protein in that lane. By stripping the blot and re-probing with an antibody against a housekeeping protein (like actin or tubulin), you can normalize your protein P signal to the amount of total cellular protein actually loaded. Only after this normalization can you confidently conclude that protein P levels per cell have truly increased.
Option A addresses antibody specificity, which is important for confirming you're detecting the right protein, but doesn't solve the quantification problem. Option C suggests using a different antibody, which could help verify results but again doesn't address the core issue of loading variability. Option D mentions measuring protein concentration before loading, which is good practice, but measuring and actually loading equal amounts are different things—pipetting errors and other variables can still create unequal loading.
Remember: In any quantitative Western blot experiment, loading controls are your safety net. Without proper normalization, even dramatic band intensity differences could be experimental artifacts rather than real biological changes.
- A researcher investigates a mutation's effect on an enzyme's thermal stability. They create one batch of purified wild-type (WT) protein and one batch of mutant protein. They test five aliquots from the mutant batch and five from the WT batch, finding the mutant protein loses activity faster at 50°C. They conclude the mutation decreases the enzyme's stability. What is a major limitation of this experimental design?
Answer: The use of a single purification batch for each protein type means any observed difference could be due to a batch-specific artifact rather than the mutation itself.
When evaluating experimental design in biochemistry, you must always consider whether the observed results truly reflect the biological phenomenon being studied or could be explained by experimental artifacts. This question tests your ability to identify confounding variables that could invalidate conclusions.
The major flaw here is that each protein type was prepared as a single batch, then divided into aliquots for testing. Even though five aliquots were tested from each batch, all the mutant samples came from one preparation and all the wild-type samples came from another preparation. Any difference in thermal stability could therefore result from batch-to-batch variation in the purification process rather than the mutation itself. Perhaps the mutant batch had slightly different buffer conditions, protein concentration, or contaminating proteases that affected stability. Answer D correctly identifies this critical design flaw.
Let's examine why the other options miss the mark: Answer A is incorrect because control proteins from other organisms aren't necessary to compare two versions of the same enzyme. Answer B misunderstands statistics—the issue isn't sample size but rather that the samples aren't truly independent since they come from single batches. Answer C raises a valid scientific question about physiological relevance, but this doesn't represent a fundamental experimental design flaw that would invalidate the conclusion about relative stability differences.
Study tip: In protein biochemistry experiments, always look for proper controls and replication. True biological replicates require independent preparations (multiple batches), not just multiple measurements from the same preparation (technical replicates). This distinction frequently appears on biochemistry exams.
- A researcher investigates the effect of a hydrophobic drug on a kinase cascade in cultured hepatocytes. The drug is dissolved in dimethyl sulfoxide (DMSO) before being added to the cell culture medium. A Western blot shows that target protein phosphorylation increases after treatment. What is the most appropriate negative control to ensure the observed effect is due to the drug itself?
Answer: Cells cultured with an equivalent volume of DMSO added to the medium.
When a substance (like a drug) is dissolved in a solvent (vehicle) for delivery, it is crucial to test for effects of the vehicle alone. DMSO is known to have biological effects on its own. Therefore, a 'vehicle control' (A) where cells are treated with just DMSO is essential to ensure that the observed phosphorylation is a result of the drug, not its solvent. Untreated cells (B) are a baseline but don't control for DMSO. An inactive analog (C) is an excellent control for specificity, but the vehicle control is more fundamental. A knockout (D) helps identify the drug's target but does not address the solvent issue.
